Status:
COMPLETED
Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Osteoporosis
Eligibility:
MALE
25-85 years
Phase:
PHASE3
Brief Summary
The goal of this study is to determine the effectiveness and safety of an annual intravenous treatment of zoledronic acid for the treatment of osteoporosis in men. All patients will receive calcium an...
Eligibility Criteria
Inclusion
- Male, 25-85 years old
Exclusion
- Current users of bisphosphonates such as Aredia® (pamidronate), Didronel® (etidronate), Fosamax® (alendronate), Actonel ® (residronate), Skelid® (tiludronate)
- History of severe liver, kidney or eye disease
- Other protocol-defined inclusion/exclusion criteria may apply.
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
End Date :
August 1 2007
Estimated Enrollment :
288 Patients enrolled
Trial Details
Trial ID
NCT00097825
Start Date
April 1 2004
End Date
August 1 2007
Last Update
April 27 2012
Active Locations (26)
Enter a location and click search to find clinical trials sorted by distance.
1
Catalina Pointe Clinical Research Inc.
Tucson, Arizona, United States, 85704
2
Diablo Clinical Research
Walnut Creek, California, United States, 94598
3
Colorado Center for Bone Research
Lakewood, Colorado, United States, 80227
4
Radiant Research
Stuart, Florida, United States, 34996